Immunoglobulins and cancer
Cancer adjuvant treatment
Introduction
Immunoglobulins (Ig) are antibodies produced by B cells and plasma cells and are responsible for identifying and neutralizing foreign pathogens in the body, such as bacteria and viruses. Its main types include IgA, IgG, IgM, IgE and IgD, each with specific functions. In cancer, abnormal expression of immunoglobulins may affect the occurrence and progression of the disease. For example, certain tumors cause abnormally high or low levels of immunoglobulins, and specific types of immunoglobulins can also serve as diagnostic and predictive biomarkers. In addition, studies have found that immunoglobulins play a regulatory role in the tumor immune microenvironment and have a certain impact on the growth and spread of cancer cells.
What is Immunoglobulin?
Immunoglobulin, commonly known as antibodies, are proteins produced by the immune system to identify and neutralize harmful substances such as bacteria, viruses, and abnormal cells. Derived from human plasma, immunoglobulin therapy is designed to boost or modulate the immune system, supporting the body in its fight against diseases, including cancer.
How Immunoglobulin Works in Cancer Care
Cancer often weakens the immune system, making it harder for the body to combat abnormal cell growth. Immunoglobulin therapy serves as an innovative solution to this challenge.
- Enhances Immune Surveillance: Helps the immune system detect and target cancer cells more effectively.
- Reduces Inflammation: Modulates the immune response, reducing inflammation that can promote tumor growth.
- Fights Infections: Protects against secondary infections, which are common in cancer patients with compromised immunity.
- Supports Treatment Efficacy: Complements chemotherapy, radiation, or immunotherapy by fortifying the patient’s immune defenses.
Applications of Immunoglobulin in Cancer Treatment
Immunoglobulin therapy is particularly beneficial in the following scenarios:
- Support for Immunodeficient Patients: Enhances immunity in patients with weakened immune systems due to cancer or its treatments.
- Reduction of Side Effects: Alleviates complications like infections or autoimmune responses.
- Treatment of Hematological Cancers: Used as an adjunct therapy for cancers like lymphoma, leukemia, and multiple myeloma.
- Improved Quality of Life: Boosts overall resilience, allowing patients to better tolerate other treatments.
Caution: Suitability and Restrictions
Who Can Benefit:
- Patients with recurrent infections or immunodeficiency due to cancer treatments.
- Individuals undergoing chemotherapy, radiation, or stem cell transplantation.
- Patients with hematological cancers like leukemia or lymphoma.
Who Should Avoid:
- Patients with severe allergic reactions to human plasma-derived products.
- Individuals with conditions that increase the risk of blood clots.
- Those with IgA deficiency and a history of anaphylaxis to IgA.
- Pregnant or breastfeeding women without proper medical evaluation.
Always consult a qualified healthcare provider to determine suitability.
Scientific Evidence Supporting Immunoglobulin Therapy
Immune Modulation: Research demonstrates that immunoglobulin helps restore balance in immune function.
- Infection Prevention: Clinical trials confirm its effectiveness in reducing infection rates in immunosuppressed patients.
- Anti-Tumor Effects: Studies suggest that certain immunoglobulin formulations may directly inhibit tumor growth.
Reference Articles
- Orange, J.S., et al. (2006). “Use of intravenous immunoglobulin in human disease: A review of evidence by members of the Primary Immunodeficiency Committee.” Journal of Allergy and Clinical Immunology.
- Florescu, D.F., & Kalil, A.C. (2014). “The use of immunoglobulin therapy in the treatment of cancer-related infections.” Clinical Infectious Diseases.
- Kazatchkine, M.D., & Kaveri, S.V. (2001). “Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin.” New England Journal of Medicine.
- Stiehm, E.R. (2013). “The use of immunoglobulin in cancer therapy.” Clinical and Experimental Immunology.
- Jolles, S., et al. (2005). “Clinical uses of intravenous immunoglobulin.” Medicine.